Article Japanese Consensus Document on NexoBrid®, a Burn Eschar Removal Agent Hajime Matsumura 1, * , Takahiro Ueda 2 , Rei Ogawa 3 , Yasuhiko Kaita 4 , Hiroyuki Sakurai 5 , Kazutaka Soejima 6 and Junichi Sasaki 7 1 2 3 4 5 6 7 Department of…
Article
Japanese Consensus Document on NexoBrid®, a Burn Eschar
Removal Agent
Hajime Matsumura 1, * , Takahiro Ueda 2 , Rei Ogawa 3 , Yasuhiko Kaita 4 , Hiroyuki Sakurai 5 ,
Kazutaka Soejima 6 and Junichi Sasaki 7
1
2
3
4
5
6
7
Department of Plastic and Reconstructive Surgery, Tokyo Medical University, 6-7-1 Nishishinjyuku,
Shinjukuku, Tokyo 160-0023, Japan
Advanced Emergency and Critical Care Medical Center, Tottori University Hospital, Yonago, Tottori 683-8504,
Japan; [email protected]
Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical School Hospital, Bunkyo-ku,
Tokyo 113-8603, Japan; [email protected]
Department of Trauma and Critical Care Medicine, Kyorin University School of Medicine, Mitaka,
Tokyo 181-8611, Japan
Department of Plastic and Reconstructive Surgery, Tokyo Women’s Medical University, Shinjuku-ku,
Tokyo 161-8666, Japan; [email protected]
Department of Plastic and Reconstructive Surgery, Nihon University School of Medicine, Itabashi-ku,
Tokyo 173-8610, Japan; [email protected]
Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Shinjuku-ku,
Tokyo 160-8582, Japan; [email protected]
Correspondence: [email protected]; Tel.: +81-3-3342-6111
Highlights
What are the main findings?
•
•
A Japan-specific Delphi consensus on NexoBrid® was developed by seven burn specialists.
27 statements were formulated, of which 21 achieved expert consensus.
What are the implications of the main findings?
•
•
The consensus provides practical, Japan-adapted guidance for the safe and effective
use of NexoBrid® .
It helps clinicians make evidence-informed decisions when applying NexoBrid® in
diverse burn scenarios.
Abstract
Received: 6 March 2026
Revised: 25 April 2026
Accepted: 11 May 2026
Published: 13 May 2026
Copyright: © 2026 by the authors.
Published by MDPI on behalf of the
European Burns Association. Licensee
MDPI, Basel, Switzerland. This article
is an open access article distributed
under the terms and conditions of the
Creative Commons Attribution
Background: NexoBrid® (NXB), an enzymatic debridement agent approved in Japan in
2022, provides a less invasive alternative to surgical excision for burn treatment. However,
its optimal therapeutic benefit depends on appropriate patient selection and proper application technique. Existing international consensus documents are not fully applicable to
clinical practice in Japan because of differences in available devices and drugs. Therefore,
a Japan-specific consensus document was developed by a panel of seven Japanese burn
experts, including four plastic surgeons and three emergency physicians. Methods: A
questionnaire-based survey was conducted using the Delphi method to achieve expert consensus. Consensus was defined as agreement by at least 80% of committee members for each
statement. A total of 27 statements were evaluated over two rounds. Results: Consensus
was achieved for 20 of 27 statements (74.1%) in the first round and for 21 of 27 statements
(77.8%) in the second round. The finalised statements were organised into seven categories according to their attributes: indications, pain management, application timing,
application technique, post-application wound care, skin grafting, and scarring/aesthetic
(CC BY) license.
Eur. Burn J. 2026, 7, 29
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
2 of 16
outcomes. Conclusions: This consensus document integrates the opinions of plastic surgeons and emergency physicians in Japan, while also incorporating relevant international
perspectives, to provide practical guidance on the use of NXB for burn treatment. It is
intended to improve the quality of burn care by clarifying efficacy, safety, and precautions
associated with NXB use. These recommendations should be updated as further clinical
experience accumulates.
Keywords: burn eschar; early removal; enzymatic debridement; purified product of
pineapple stem juice extract; statement
-
Introduction
Eschar from burns often becomes an environment conducive to bacterial proliferation
and worsens prognosis in burn patients when infection or sepsis develops. Local inflammation further damages surrounding healthy tissues, and the progression of the burn wound
deteriorates the patient’s overall condition, underscoring the importance of early eschar
removal. The Japanese Clinical Practice Guidelines for the Management of Burn Care
recommend early eschar removal for extensive burns in the early phase following injury
(within one week) [1].
Surgical excision remains the standard of care for eschar removal. It reliably removes
necrotic tissue; however, excessive debridement or excision may result in unnecessary
removal of viable tissue [2]. It also causes substantial blood loss and is often difficult to
perform early after injury when the patient’s condition is unstable. NexoBrid® (NXB) can
address these limitations and is widely used for early eschar removal in Japan and other
countries. NXB is a topical enzyme formulation derived from pineapple stems that lyses
and removes eschar after four hours of application. Given that it exhibits high enzymatic
activity against gelatine generated by thermal denaturation of dermal collagen, NXB is
considered to act selectively on eschar. Hence, it is particularly useful at anatomical sites
where preservation of healthy tissue is critical for functional or aesthetic outcomes, such
as the hands and face. Moreover, a clinical study reported less blood loss with NXB than
with surgical excision [3]. To maximise the benefits of NXB, clinicians must understand
appropriate case selection and correct use.
In countries where NXB was approved earlier, mainly in Europe, consensus documents
have been released that outline candidate wounds and recommendations for wound care
and skin grafting after NXB application [4–8]. Although it has demonstrated treatment
efficacy since the start of clinical use in Japan, numerous cases have been recorded with
inadequate responses or challenging wound care after NXB application. Despite the release
of multiple overseas consensus documents, none are fully applicable to Japan because
available dressings, medical devices and drugs differ between Japan and other countries.
Therefore, here, we aimed to develop a Japan-specific consensus document in order to
better guide burn care employing NXB-based treatment.
This article is an English translation of a consensus document originally published
in Japanese in the Japanese Journal of Burn Injuries, Volume 52, Issue 1 (March 2026) [9],
reproduced with permission from the copyright holder.
-
Materials and Methods
Consensus development was conducted using the Delphi method, which summarises
expert opinions through multiple rounds of anonymous questionnaires [10]. The consensus committee consisted of seven members: four plastic surgeons and three emergency
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
3 of 16
physicians selected based on the following criteria: extensive experience and expertise in
burn treatment, clinical experience with NXB, and recognition as Japanese burn experts.
Statements were initially drafted based on previous studies and refined through multiple panel meetings. During these meetings, statements addressing issues and questions
encountered in clinical practice in Japan were added.
Consensus formation occurred in the following sequence:
First round: Committee members answered the questionnaire without knowledge of
other members’ responses.
Second round: Committee members completed a second questionnaire while reviewing anonymized first-round responses.
The questionnaire included the following five choices:
1.
2.
3.
4.
5.
Strongly agree.
Agree.
Neither agree nor disagree.
Disagree.
Strongly disagree.
Agreement was defined as selecting “1” or “2”, while consensus was established when
agreement among 80% or more committee members concurred, indicating that at least
six of the seven members agreed. After the second round, a panel meeting was convened
to discuss whether any statements required revocation or modification. Statements were
finalised with the agreement of all committee members.
- Results
A total of 27 statements were formulated and classified into seven categories: indication, pain management, application timing, application technique, wound care after
application, skin grafting, and scarring (aesthetics).
In the first round, agreement was achieved for 20 of the 27 statements (74.1% agreement; disagreement: statements 4, 5, 6, 17, 18, 23, and 26). In the second round, agreement
was achieved for 21 of the 27 statements (77.8% agreement; disagreement: statements
4, 5, 17, 18, 23, and 26; Table 1). After the second-round questionnaire, a panel meeting
determined that no re-voting was required to modify five statements (Statements 1, 10, 13,
14, and 25), after which the statements and consensus were finalised.
Table 1. Japanese consensus statements and results of voting as obtained via the Delphi method.
No.
Category
Statement
NexoBrid® is advisable for
1
Indications
application to burn wounds with
mixed depth burn patterns.
Result
Strongly agree: 1
Agree: 6
2
Indications
NexoBrid® is very beneficial when
applied to burns in critical areas (face,
hands and feet, perineum, etc.).
3
Indications
Paediatric or elderly patients are good
candidates for NexoBrid® .
Strongly agree: 1
Agree: 5
Neither agree nor disagree: 1
Indications
The use of NexoBrid® in
circumferential burns of the
extremities in the early phase
following injury can avoid
surgical escharotomy.
Agree: 3
Neither agree nor disagree: 4
4
Strongly agree: 4
Agree: 3
Agreement
×
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
4 of 16
Table 1. Cont.
No.
Category
Statement
The use of NexoBrid® can complete
debridement of the whole burn
wound in the early phase
following injury.
Result
Agreement
Strongly agree: 2
Agree: 3
Neither agree nor disagree: 2
×
5
Indications
6
Indications
Chemical burns and electrical burns
are not amenable to NexoBrid® .
Strongly agree: 4
Agree: 2
Neither agree nor disagree: 1
7
Indications
NexoBrid® shows inadequate efficacy
in burns caused by low temperatures
(less than 70 ◦ C).
Strongly agree: 2
Agree: 4
Neither agree nor disagree: 1
Indications
NexoBrid® is less likely to be
efficacious in third-degree burns
involving damage extending into the
subcutaneous tissue and in areas of
dry black eschar.
Strongly agree: 2
Agree: 4
Neither agree nor disagree: 1
9
Indications
Pretreatment before NexoBrid® with
topical agents or dressings containing
silver or iodine should be avoided.
Strongly agree: 6
Agree: 1
10
Indications
Any blister roofs or epidermal keratin
should be removed before the
application of NexoBrid® .
Strongly agree: 6
Agree: 1
11
Indications
NexoBrid® should not be applied
directly on surgical escharotomy
wounds and macerated wounds.
Strongly agree: 5
Agree: 2
12
Pain
management
Appropriate pain management is
needed at the application and
removal of NexoBrid® .
Strongly agree: 7
13
Pain
management
Local anesthesia or nerve blocking is
useful in cases of injuries limited to
the extremities.
Strongly agree: 3
Agree: 4
14
Application
timing
NexoBrid® is more likely to be
beneficial when applied in the early
phase following injury.
Strongly agree: 3
Agree: 4
15
Application
timing
Burn wounds that are immediately
after injury and still adequately moist
do not require pre-soaking.
Strongly agree: 2
Agree: 5
16
Application
timing
Burn wounds in which necrotic
tissues have hardened over time after
injury need to be adequately
macerated with
prolonged presoaking.
Strongly agree: 3
Agree: 4
17
Application
Technique
Burn depth can be determined by the
color or bleeding pattern after
application of NexoBrid® .
Strongly agree: 3
Agree: 1
Neither agree nor disagree: 3
×
18
Wound care
after application
Antiseptic solutions should be used
after soaking whenever possible.
Strongly agree: 1
Agree: 1
Neither agree nor disagree: 5
×
8
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
5 of 16
Table 1. Cont.
No.
Category
Statement
Result
19
Wound care
after application
Pseudo-eschar is a surface debris to
the wound surface that originates
from exudate fluid or drug residues
after removal of NexoBrid® .
Strongly agree: 4
Agree: 3
20
Wound care
after application
To determine eschar removal and
differentiate from pseudo-eschar
formation, images should be captured
at three time points: before
application of NexoBrid® , after
application of NexoBrid® , and after
post-soaking.
Strongly agree: 6
Agree: 1
21
Wound care
after application
Aggressive removal of pseudo-eschar
is not necessary.
Strongly agree: 1
Agree: 5
Disagree: 1
22
Wound care
after application
After post-soaking, the wound
surface should be a
moist environment.
Strongly agree: 5
Agree: 2
23
Wound care
after application
A reddish black wound surface after
removal of NexoBrid® heals
spontaneously with
conservative treatment.
Agree: 1
Neither agree nor disagree: 5
Disagree: 1
24
Wound care
after application
Trafermin is effective even in wounds
after NexoBrid® removal.
Strongly agree: 2
Agree: 5
25
Skin grafting
Skin grafting should be performed
immediately if spontaneous
epithelialization is less likely to occur
after NexoBrid® removal.
Strongly agree: 7
26
Skin grafting
Skin grafting is also feasible on the
day of application of NexoBrid® .
Strongly agree: 1
Agree: 2
Neither agree nor disagree: 4
27
Scarring
(esthetics)
NexoBrid® provides an aesthetically
more favorable outcome than
surgical excision.
Strongly agree: 2
Agree: 4
Neither agree nor disagree: 1
Agreement
×
×
indicates agreement; × indicates disagreement.
3.1. Statements with Agreement Achieved
3.1.1. NexoBrid® Is Advisable for Application to Burn Wounds with Mixed Depth Burn
Patterns (All Seven Consensus Committee Members Agreed (7/7))
As NXB selectively removes eschar, its use is desirable in mixed-depth burn patterns
that consist primarily of deep dermal burns (DDB). Mixed-depth patterns may include
superficial dermal burns (SDB), but NXB is indicated for use in DDB and deep burns (DB).
Therefore, it should not be applied to burn wounds that consist only or predominantly
of SDB. Committee members have encountered mixed post-marketing cases involving
SDB and DDB, including cases where intradermal hematomas in SDB failed to resolve and
subsequently progressed to necrosis, complicating management after NXB application.
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
6 of 16
3.1.2. NexoBrid® Is Advantageous When Applied to Burns in Critical Areas (Such as the
Face, Hands, Feet, and Perineum) (7/7)
As NXB is a topical formulation, it can be easily applied to anatomically complex
areas where surgical excision is technically difficult [11–14]. In addition, its eschar-selective
debridement preserves dermal components, potentially contributing to favourable aesthetic
outcomes and functional outcomes.
3.1.3. Paediatric or Elderly Patients Are Good Candidates for NexoBrid® (6/7)
Given that NXB is associated with less blood loss than surgical excision [3], it may be
beneficial for elderly patients with unstable general conditions early after injury. It can also
reduce the need for surgery (e.g., surgical debridement or skin grafting) or the extent of
surgery [15], rendering it useful for elderly patients for whom minimally invasive treatment
is preferred. However, caution is warranted in elderly patients, as delayed wound healing
or recurrent necrosis may occur when peripheral circulation is compromised (e.g., by
arteriosclerosis or diabetes) [16].
A review of clinical and controlled studies comparing the standard of care has shown
that NXB reduces the need for surgery or the extent of surgery in paediatric patients [17,18],
indicating its usefulness in paediatric burns, which carry a substantial psychological burden
for patients and families. However, NXB in paediatric patients is associated with procedurerelated pain, potentially rendering the maintenance of a resting state for four hours difficult
in a patient; therefore, appropriate analgesic and sedative management is required.
3.1.4. Chemical Burns and Electrical Burns Are Not Amenable to NexoBrid® (6/7)
Although this statement did not achieve agreement in the first round (5/7), consensus
was reached in the second round (6/7). No clinical studies have been conducted on the
effects of NXB in chemical or electrical burns. Although debridement completion with
NXB has been reported in three of four cases of chemical burns and both cases of electrical
burns [19], and NXB may be beneficial in the presence of denaturation to gelatine, the
number of reported cases was insufficient to support a recommendation. One committee
member had experience with the product for a case of chemical burns (alkali) but observed
an inadequate response.
3.1.5. NexoBrid® Shows Inadequate Efficacy in Burns Caused by Low Temperatures (Less
than 70 ◦ C) (6/7)
NXB acts on gelatine generated by the thermal denaturation of dermal collagen. In
burns caused by low temperatures, gelatinization is incomplete, reducing NXB efficacy.
Thus, the use of NXB requires confirmation of the mechanism and type of injury.
3.1.6. NexoBrid® Is Less Likely to Be Efficacious in Third-Degree Burns Involving Damage
Extending into the Subcutaneous Tissue and in Areas of Dry Black Eschar (6/7)
As NXB exerts its effects via gelatinase activity, it is less likely to act on adipose tissue.
Therefore, it may be less efficacious in third-degree burns with thermal injury extending
into the subcutaneous tissue. In addition, in dry necrotic tissue, such as black eschar,
drug penetration throughout the necrotic tissue is less likely, reducing efficacy. If NXB
is to be applied in such cases, the eschar should be adequately macerated by overnight
pre-soaking (from the day before to immediately before application). Additional useful
strategies include making an incision in the eschar before application of NXB to facilitate
penetration or performing surgical excision of (only the superficial eschar layer to the extent
that bleeding does not occur.
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
7 of 16
3.1.7. Pretreatment Before NexoBrid® with Topical Agents or Dressings Containing Silver
or Iodine Should Be Avoided (7/7)
Since silver or iodine inhibits the enzymatic activity of NXB, topical agents or dressings
containing these substances should not be used before NXB application [20]. Moreover,
occlusive dressings containing silver or iodine should not be used during the 4 h period
while NXB is in place. As the previous physician may have used topical agents or dressings
containing silver or iodine, prior use should be verified before applying NXB. Notably,
topical agents or dressings containing silver or iodine may be used for wound care after
completion of the post-soaking following NXB application.
3.1.8. Any Blister Roofs or Epidermal Keratin Should Be Removed Before the Application
of NexoBrid® (7/7)
Considering that NXB-mediated eschar removal requires direct enzymatic contact
with the eschar, any physical barriers, such as blister roofs (epidermal keratin layers), must
be removed. If blister roofs are present, they may indicate SDB, in which case NXB should
not be applied.
3.1.9. NexoBrid® Should Not Be Applied Directly to Surgical Escharotomy Wounds and
Macerated Wounds (7/7)
In a single-dose and repeat-dose intravenous toxicity study in pigs, changes in blood
coagulation parameters and bleeding tendency were observed [21]. In clinical settings, a
post-marketing survey in Japan reported five bleeding-related adverse drug reactions in
five patients, with three events in three patients classified as serious. Of the serious events,
two in two patients may have occurred as a result of NXB contacting relaxed incision
wounds [22]. To prevent bleeding, NXB should not be applied to surgical escharotomy or
macerated wounds. If NXB is applied in such cases, the wounds should be protected with
Vaseline ointment or gauze coated with Vaseline ointment.
3.1.10. Appropriate Pain Management Is Needed at the Application and Removal of
NexoBrid® (7/7)
As pain occurs during the application and removal of this drug, pain management
should be initiated before both procedures. In particular, as body movements may impair
the efficacy of NXB or cause adverse events in children, adequate sedative and analgesic
management is required.
3.1.11. Local Anaesthesia or Nerve Blocking Is Useful in Cases of Injuries Limited to the
Extremities (7/7)
In cases of injuries limited to the extremities, this drug does not routinely need to be
used in an operating room but can be applied at the bedside for pain management with
local anaesthesia or nerve blocking. Overseas consensus documents note that burns of the
extremities are manageable under local anaesthesia [5,8].
3.1.12. NexoBrid® Is More Likely to Be Beneficial When Applied in the Early Phase
Following Injury (7/7)
NXB can be more beneficial when applied before necrotic tissues become dry. Clinical
studies have demonstrated that application within 84 h of injury is associated with high
efficacy in eschar removal [3,15,23]. In addition, early eschar removal is expected to reduce
the risk of infection. However, burns caused by high-temperature liquids may involve
inadequately denatured dermal collagen; in such cases, the drug should be applied beyond
72 h after injury [5].
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
8 of 16
3.1.13. Burn Wounds That Are Immediately After Injury and Still Adequately Moist Do
Not Require Pre-Soaking (7/7)
The European consensus document states that very early (within 12 h after injury)
cases in which necrotic tissues remain adequately moist do not require pre-soaking [5].
One committee member encountered a case in which an early application of NXB, without
pre-soaking, achieved adequate eschar removal. Given that extensive experience with
NXB is required to determine when pre-soaking can be skipped, early use of the drug
should follow the standard procedure. In contaminated burn wounds, adequate cleansing
is required regardless of whether pre-soaking is omitted.
3.1.14. Burn Wounds in Which Necrotic Tissues Have Hardened over Time After Injury
Need to Be Adequately Macerated with Prolonged Pre-Soaking (7/7)
Given that eschar removal by NXB depends on enzymatic activity, the onset of action
requires penetration into the eschar. Thus, the onset of action is less likely in dry, hardened
necrotic tissues due to insufficient penetration. If NXB is to be applied to such hard necrotic
tissues, they should be adequately macerated by pre-soaking beginning on the day before
application [4]. There was agreement that pre-soaking could be initiated the day before
application, allowing the procedure to be completed during the daytime shift.
3.1.15. Pseudo-Eschar Is a Surface Debris to the Wound Surface That Originates from
Exudate Fluid or Drug Residues After Removal of NexoBrid® (7/7)
Pseudo-eschar is a surface debris to the wound surface formed after application of
NXB and is considered different from necrotic tissues, resulting from necrosis of the zone
of stasis [4]. It is formed on a relatively shallow wound surface and may be formed as early
as immediately after post-soaking.
3.1.16. To Determine Eschar Removal and Differentiate from Pseudo-Eschar Formation,
Images Should Be Captured at Three Time Points: Before Application of NexoBrid® , After
Application of NexoBrid, and Post-Soaking (7/7)
Determining eschar removal and distinguishing pseudo-eschar from true eschar requires further investigation. Notably, wound conditions should be monitored and assessed
over time. Images should be captured and compared before the application of NXB, after
the application of NXB (immediately after removal), and immediately after soaking. If
petechial haemorrhaging is observed immediately after NXB removal but a white surface
debris is noted after post-soaking, the surface debris may be a pseudo-eschar.
3.1.17. Aggressive Removal of Pseudo-Eschar Is Not Necessary (6/7)
Pseudo-eschar is part of the healing process and does not require surgical intervention
as it spontaneously desquamates or resolves [4]. Some consider pseudo-eschar to function
as a biological dressing. However, if early wound closure is desired, removal of the
pseudo-eschar followed by skin grafting may be appropriate. This statement indicates that
preservative treatment is feasible but does not recommend excision or skin grafting.
3.1.18. After Soaking, the Wound Surface Should Be Maintained in a Moist
Environment (7/7)
Considering that post-soaking dryness may contribute to the progression of necrosis or pseudo-eschar formation, maintaining a moist environment, which can facilitate
healing and reduce the frequency of dressing replacement and the pain associated with
replacement [7]. Acceptable dressing materials include those routinely used to maintain moisture in burn treatment, such as Vaseline gauze, non-adherent silicone gauze,
and hydrocolloids.
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
9 of 16
3.1.19. Trafermin Is Effective Even for Wounds After NexoBrid® Removal (7/7)
Trafermin (FIBLAST® Spray: Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) is a formulation of recombinant human basic fibroblast growth factor indicated for the treatment
of burn ulceration. NXB is a proteolytic enzyme shown to achieve eschar removal in a
mouse burn model and does not impair burn wound healing, even when trafermin is
applied to wounds after NXB treatment [24].
3.1.20. Skin Grafting Should Be Performed Immediately if Spontaneous Epithelialization Is
Less Likely to Occur After NexoBrid® Removal (7/7)
Although overseas consensus documents suggest considering skin grafting in DDB
cases expected to heal conservatively, epithelialization may not occur even 21 days after
NXB removal [5,7,8], and some panellists support earlier grafting without waiting for
21 days. If spontaneous epithelialization is unlikely, skin grafting should be performed
immediately. Given that burns caused by high-temperature liquids may deepen after NXB
application, wounds should be carefully observed after removal, and the timing of grafting
should be determined accordingly. Standard skin grafting procedures used in routine burn
treatment are acceptable. In other countries, cryopreserved allogeneic skin grafting has
been performed after NXB application and is recommended for managing wound surfaces
that are likely or unlikely to epithelialize after post-soaking [5]. In Japan, cryopreserved
allogeneic skin grafting is managed by the Japan Skin Bank Network, and measures to
relax shipping criteria have been implemented in severe cases where NXB is used for
lifesaving purposes, although these measures are provisional [25]. However, such cases of
cryopreserved allogeneic skin grafting after NXB application remain limited in Japan and
require additional experience.
3.1.21. NexoBrid® Provides an Aesthetically More Favourable Outcome than Surgical
Excision (6/7)
NXB can preserve healthy tissues through eschar-selective debridement and is therefore expected to provide aesthetically favourable outcomes. At a one-year follow-up, an
overseas clinical study reported that the modified Vancouver Scar Scale (mVSS) was significantly more favourable in the NXB group than in the standard-of-care group [3]. In
contrast, a meta-analysis found that mVSS was more favourable in the NXB group than in
the standard care group, although this difference did not reach statistical significance [26].
Further investigation is warranted. Some panellists noted that debridement and subsequent
wound management influence aesthetic outcomes and that aesthetics may be difficult to
assess at the debridement stage alone.
3.2. Statements with No Agreement
3.2.1. The Use of NexoBrid® in Circumferential Burns of the Extremities in the Early Phase
Following Injury Can Avoid Surgical Escharotomy (3/7)
As some panellists stated that avoiding surgical escharotomy with NXB is possible
but not certain, consensus was not achieved. Some panellists expressed that appropriate
use by physicians with extensive case experience might avoid the need for surgical escharotomy. One of the panellists has encountered a case in which the use of NXB reduced
the compartment pressure in circumferential burns of the hands and forearms. Notably, a
surgical escharotomy should be immediately made in cases of established burn-induced
compartment syndrome (BICS).
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
10 of 16
3.2.2. The Use of NexoBrid® Can Complete Debridement of the Whole Burn Wound in the
Early Phase Following Injury (5/7)
NXB can be applied in the early phase after injury, when the patient’s general condition
is unstable, thereby enabling earlier completion of debridement. However, some panellists
noted that additional surgical excision may be required or that recurrent necrosis may
occur in some cases, thereby precluding agreement on this statement. To complete early
debridement after injury, appropriate case selection, adequate preparation, and accurate
assessment of wounds after NXB application are essential. In cases with extensive burns,
combining surgical excision with NXB may achieve complete debridement earlier than
surgical excision alone [27].
3.2.3. Burn Depth Can Be Determined by the Colour or Bleeding Pattern After Application
of NexoBrid® (4/7)
This statement did not reach agreement because some panellists noted that accurate
assessment requires experience and cannot be reliably performed by all clinicians, although
colour or bleeding patterns may assist in determining burn depth [28,29].
3.2.4. Antiseptic Solutions Should Be Used After Soaking Whenever Possible (2/7)
Although antiseptic solutions are not essential for post-soaking, their use is recommended when necessary. In an overseas Phase II study, fever and wound infections
occurred more frequently in the NXB group than in the standard-of-care group. In a subsequent overseas Phase III study, maceration with antiseptic solution-impregnated gauze was
used as a preventive measure, reducing the risk of fever and wound infection [30]. A 0.05%
chlorhexidine solution is commonly used as an antiseptic solution, and some overseas
institutions use a Prontosan solution [31].
3.2.5. A Reddish Black Wound Surface After Removal of NexoBrid® Heals Spontaneously
with Conservative Treatment (1/7)
A reddish-black wound surface noted after application of NXB is typically considered
the SDB site. This haematoma results from the disruption of blood vessels in the superficial
dermal layer and may resolve with conservative treatment, as it is absorbed and ultimately
resolves. However, some panellists reported cases without spontaneous healing, preventing
consensus. Panellists expressed the opinion that a wound surface often turned reddish
black after application of NXB in cases of poor microcirculation, such as elderly patients or
patients with diabetes.
3.2.6. Skin Grafting Is Also Feasible on the Day of Application of NexoBrid® (3/7)
Given that determining eschar removal requires experience and that the risk of graft
dislodgement due to residual eschar is substantial, some panellists emphasised the need
for careful assessment; consensus was not reached. However, this statement is not a
recommendation against skin grafting on the day of NXB application. The European
consensus document recommends that skin grafting should be performed at least two days
after NXB application [5]. Some panellists reported that skin grafting may be feasible on
the day of application if eschar removal is adequate and the drug is thoroughly removed
with cleansing. Although no panellists had personal experience performing grafting on
the day of NXB application, some reported favourable engraftment with grafting on the
following day. In Japan, one report described favourable outcomes when skin grafting
was performed on the day of superficial-layer removal following NXB application and
hydrosurgical debridement [32].
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
11 of 16
- Discussion
NXB, a burn eschar removal agent, is a useful alternative to surgical excision based
on its eschar-selective action, reduced blood loss, shorter time to completion of eschar
removal, and other advantages [3,15]. This consensus document summarises both Japanese
and overseas evidence, as well as the opinions of panellists with extensive experience and
expertise in burn treatment, using the Delphi method. Consequently, 27 statements were
developed, of which 21 achieved agreement (77.8% agreement rate). The agreement rate
tended to be lower than that reported in overseas consensus documents (European 2020:
97.7%, Spain: 97.2%) [5,8]. The following factors may have influenced: first, this document
adopted a policy of avoiding ambiguous terms such as “potentially” or “expected” whenever possible; second, the proportion of panellists selecting “Neither agree nor disagree”
was high, likely due to less clinical experience than in other countries, because statements
were formulated 1.5 years after the start of clinical use.
Statements aligned in content with overseas consensus documents generally provided
similar recommendations. However, Statements 4 (avoidance of surgical escharotomy),
17 (determination of burn depth based on colour and bleeding patterns), and 18 (antiseptic
solutions for post-soaking) showed different results.
Statement 4 (Avoidance of surgical escharotomy) was formulated under the policy
of avoiding ambiguous expressions such as “potentially” or “expected.” Thus, wording
indicating that surgical escharotomy “can be avoided” was used. In addition, some panellists suggested avoiding assertive recommendations because close observation is required
during the NXB application; therefore, consensus was not achieved. In contrast, several
reports have described successful avoidance of BICS when NXB was applied as early as
possible [12,33,34]. Krieger et al. [12] reported that NXB reduced compartment pressure
from 35 to 75 mmHg to 25 mmHg without performing surgical escharotomy in four patients
(seven hands). Fischer et al. [33] reported that NXB applied 2–22 h after injury avoided
surgical escharotomy in 13 patients (20 upper limbs) with deep upper-limb burns, and
Mataro et al. [34] reported reductions in compartment pressure to ≤30 mmHg within 1 h
of injury in 23 patients with circumferential extremity burns. The European consensus
document also notes the potential to avoid BICS [5]. One panellist reported a case in
which NXB reduced compartment pressure in circumferential burns of the hands and
forearms [35]. Continuous monitoring of compartment pressure before, during, and after
NXB application, involving procedures such as the subcutaneous insertion of an injection
needle and the connection of the needle to a probe for blood pressure, ensures safety.
Although agreement was not reached, early use of NXB after injury under appropriate
management by physicians with extensive clinical experience may reduce invasiveness in
circumferential burns of the extremities.
For Statement 17 (Determination of burn depth by colour and bleeding patterns),
some panellists stated that burn depth could be predicted from the colour or bleeding
pattern of wounds after NXB application, but that accurate assessment requires experience;
therefore, consensus was not achieved. Reports differ regarding the interpretation of a
homogeneous reddish-black wound surface after NXB application: one suggests that it
may allow spontaneous epithelialization because much of the dermis remains (DDB close
to SDB) [28], whereas another indicates that it may represent DDB requiring prolonged
epithelialization or, in some cases, skin grafting [29]. The discrepancy between these reports
suggests that wound evaluation after NXB application can be difficult.
For Statement 18 (Antiseptic solutions for post-soaking), a substantial proportion
of panellists chose “Neither agree nor disagree” due to concerns regarding the cytotoxic
potential of antiseptic solutions; therefore, agreement was not achieved. However, antiseptic solutions are recommended when necessary. In an overseas Phase II study that
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
12 of 16
did not recommend post-soaking with antiseptic solutions, the incidences of fever and
wound infection were higher in the NXB group than in the standard-of-care group. In a
subsequent overseas Phase III study, post-soaking with antiseptic solutions reduced the
risks of fever and wound infection [30]. Accordingly, Japan’s risk management plan (RMP)
identified fever and wound infection as important risks. Overseas package inserts state that
antiseptic solution soaking should be performed [36], whereas the Japanese package insert
notes that antiseptic solutions may be used as needed but does not mandate their use [24].
Nevertheless, the use of antiseptic solutions is advisable to reduce the risks of fever and
wound infection as described above. One major cause of fever after application of the NXB
occlusive dressing for 4 h is the insulating properties of the dressing that reduce normal
heat dissipation. In surgery, using an occlusive dressing (a simple autoclaved polyurethane
garbage bag) can keep a patient warm in cold operating rooms but often leads to excessive
warming after a couple of hours, necessitating opening the occlusive dressing to dissipate
the heat. One purpose of post-NXB soaking is to facilitate heat dissipation. Although
concerns exist regarding the cytotoxic potential of antiseptic solutions, an in vitro study
reported that chlorhexidine reduces cell viability in a concentration-dependent manner;
however, the chlorhexidine concentration used for post-soaking (0.05%) is low and is
therefore considered to have limited effects after two hours of soaking [37].
NXB is a topical formulation that is easy to use but requires appropriate wound care
before application to maximise its therapeutic efficacy. The eschar removal by NXB is based
on an enzymatic reaction and is inhibited by topical agents or dressing materials containing
silver or iodine, which should not be used for wound care before application. Occlusive
dressing used during the four-hour period in which the drug is kept in place should also not
contain silver or iodine. Although it is acceptable to use topical agents or dressing materials
containing silver or iodine after the post-soaking, following application of NXB, caution
should be exercised because the use of topical agents or dressing materials containing silver
is likely to cause the formation of pseudo-eschar tissue. In addition, because an adequate
response to NXB itself needs to contact with necrotic tissue, hard necrotic tissue should
be adequately moistened or macerated before NXB application. The enzymatic activity
of NXB, consistent with the behaviour of all other enzymes, occurs within tissue that
possesses sufficient moisture content. The eschar, which is the substrate for this enzymatic
activity, should therefore remain sufficiently moist. Although package inserts explain that
pre-soaking to reduce the bacterial load and moisten the eschar should be performed for
approximately two hours, many institutions perform overnight pre-soaking in cases where
some time has passed since injury. Skipping pre-soaking is acceptable for adequately moist
and clean necrotic tissues when using NXB in the very early period after burn injury [5]. In
addition, it should be noted that an appropriate volume relative to the area of application
(one 5 g kit per 450 cm2 ) should be used.
Since the use of NXB provides eschar-selective debridement, decreases in the percentage of cases undergoing skin grafting and the area of skin grafting have been reported [15].
Although NXB is more likely to preserve the dermis necessary for a normal epithelialization
process than conventional surgical excision, it should be used with the understanding that
spontaneous epithelialization is not possible in all cases. The need for skin grafting has
to be considered after carefully observing the wound surface before and after the application of NXB. For the timing of skin grafting, overseas consensus documents recommend
considering skin grafting at 21 days or later in cases of delayed epithelialization despite
preserved dermis [5], whereas this consensus document includes opinions supporting skin
grafting without waiting for 21 days. Skin grafting should, in particular, be performed
early at sites that are likely to present with scar contracture. Caution should be exercised
because the development of pseudo-eschar, especially in dermal wounds (SDB and DDB),
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
13 of 16
may interfere with graft take. In addition, for DB, the European consensus document recommends skin grafting at least two days after the application of NXB, whereas the Spanish
consensus document recommends grafting at three to five days after the application of
NXB [5,8]. This consensus document states that skin grafting may be performed less than
two days after the application of NXB only in wounds in which complete eschar removal is
considered to have been achieved with no drug residue. Deeper wounds usually have less
pseudo-eschar formation. In Japan, a report described skin grafting performed on the day
of the application of NXB [32], but the evidence is considered insufficient and did not lead
to a recommendation (Statement 26). It should be noted that one panellist encountered a
case in which skin grafting was performed on the day after the application of NXB with
favourable outcomes. However, in some cases, another reason for delaying grafting by a
day or more after NXB is practical from the perspective of workload distribution. More
cases will be required to determine the optimal timing of grafting.
NXB must be used with an understanding of its characteristics and, in selected cases,
to leverage its strengths. More specifically, such cases include burns in critical areas (face,
hands, feet, and the perineal region) where surgical excision is technically difficult. Given
that these areas are aesthetically and functionally important, NXB, which can selectively
remove eschar, is useful. In addition, children and elderly individuals with very thin
skin, which challenges the preservation of the non-injured dermis and for whom surgical
stress should be avoided, are also good candidates. For elderly people, wound healing
may be delayed, or recurrent necrosis may occur after the application of NXB in cases of
poor peripheral circulation (such as arteriosclerosis and diabetes [16]), and further study
is warranted.
Thermal denaturation of collagen has been reported to occur rapidly at 65 ◦ C [38].
In addition, a study investigating the efficacy of NXB in eschar removal in human tissue
(in vitro) simulating burns at 40 ◦ C to 100 ◦ C reported evidence of collagen denaturation at
≥60 ◦ C and efficacy of NXB at ≥70 ◦ C, with no evidence of efficacy at ≤50 [39]. In clinical
settings, a significantly higher proportion of burns caused by high-temperature liquids
required the addition of surgical excision than burns caused by flame [40]. However, several
controlled studies, including burns caused by various mechanisms of injury, reported
favourable efficacy [41,42], and application may be acceptable in burns caused by heat at
≥70 ◦ C.
Cases not suitable for NXB include dry and hard necrotic tissue, where the drug is less
likely to penetrate, and cases previously treated with topical agents or dressings containing
silver or iodine. There is not sufficient evidence to make recommendations for its use in
chemical burns and electrical burns. In particular, with chemical burns, it is difficult to
determine whether gelatinization has occurred, and careful application is necessary. NXB is
not suitable for low-temperature burns because gelatinization is unlikely to have occurred,
which may result in inadequate efficacy.
This consensus document was developed to reflect clinical experience in Japan by
referencing overseas consensus documents. While not included in overseas consensus
documents, three original statements on pseudo-eschar tissue were formulated in Japan
(Statements 19, 20, and 21). Pseudo-eschar is an important consideration in making full
use of NXB. This consensus document will contribute to improving the quality of burn
treatment with NXB because it describes methods for differentiating and managing pseudoeschar. Recommendations included in this consensus document are not invariable and
have to be updated as clinical experience accumulates or new evidence becomes available.
The proper use of NXB for chemical burns, electrical burns, and scald burns warrants
further investigation. In this consensus document, the formulation of statements and the
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
14 of 16
formation of agreement occurred based on evidence from clinical studies, but the results
also incorporated the opinions of panellists.
- Conclusions
This consensus document integrates the opinions of Japanese plastic surgeons and
emergency physicians with extensive experience in treating burns, along with evidence
collected in Japan and overseas, to provide recommendations on the efficacy, safety, and
precautions of NXB in burn treatment. These recommendations will help improve the
quality of care for burn treatments with NXB in Japan.
Author Contributions: Conceptualization, H.M.; writing—original draft preparation, H.M.; writing—
review and editing, H.M., T.U., R.O., Y.K., H.S., K.S. and J.S. All authors have read and agreed to the
published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable. This study did not involve human participants, personal data, or interventions requiring ethics approval.
Informed Consent Statement: Not applicable. This study did not involve human participants or
patient-level data.
Data Availability Statement: No new data were created or analysed in this study. Data sharing is
not applicable to this article.
Acknowledgments: We appreciate the scientific advice and support provided by Takuya Nabeshima
and Hiroshi Miyama of the Medical Affairs Department, Kaken Pharmaceutical Co., Ltd. This is a
translation of Japanese Consensus Document on NexoBrid® , a burn eschar removal agent originally
published in Japan by the Japanese Society for Burn Injuries in Japanese Journal of Burn Injuries, 2026,
Volume 52, Issue 1 [9]. This translation was prepared by authors. Permission was granted by the
Japanese Society for Burn Injuries.
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
The following abbreviations are used in this manuscript:
NXB
DDB
SDB
DB
mVSS
BICS
RMP
NexoBrid
deep dermal burn
superficial dermal burn
deep burn
modified Vancouver Scar Scale
burn-induced compartment syndrome
risk management plan
References
1.
Sasaki, J.; Matsushima, A.; Ikeda, H.; Inoue, Y.; Katahira, J.; Kishibe, M.; Kimura, C.; Sato, Y.; Takuma, K.; Tanaka, K.; et al. The
Japanese Society for Burn Injuries (JSBI) clinical practice guidelines for management of Burn Care (3rd Edition). Acute Med. Surg.
2022, 9, e739. [CrossRef]
Gurfinkel, R.; Rosenberg, L.; Cohen, S.; Cohen, A.; Barezovsky, A.; Cagnano, E.; Singer, A.J. Histological assessment of tangentially
excised burn eschars. Can. J. Plast. Surg. 2010, 18, 33–36. [CrossRef]
Shoham, Y.; Rosenberg, L.; Hickerson, W.; Goverman, J.; Iyer, N.; Barrera-Oro, J.; Lipovy, B.; Monstrey, S.; Blome-Eberwein, S.;
Wibbenmeyer, L.A.; et al. Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial.
J. Burn Care Res. 2024, 45, 297–307. [CrossRef] [PubMed]
Hirche, C.; Citterio, A.; Hoeksema, H.; Koller, J.; Lehner, M.; Martinez, J.R.; Monstrey, S.; Murray, A.; Plock, J.A.; Sander, F.; et al.
Eschar removal by bromelain based enzymatic debridement (Nexobrid® ) in burns: An European consensus. Burns 2017, 43,
1640–1653. [CrossRef]
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
15 of 16
Hirchem, C.; Almeland, S.K.; Dheansa, B.; Fuchs, P.; Governa, M.; Hoeksema, H.; Korzeniowski, T.; Lumenta, D.B.; Marinescu,
S.; Martinez-Mendez, J.R.; et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid® ) in burns: European
consensus guidelines update. Burns 2020, 46, 782–796. [CrossRef] [PubMed]
Korzeniowski, T.; Strużyna, J.; Chrapusta, A.M.; Krajewski, A.; Kucharzewski, M.; Piorun, K.; Nowakowski, J.; Suroqiecka, A.;
Kozicka, M.; Torres, K. A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by
Bromelain-Based Enzymatic Debridement (Nexobrid® ) in Burns Following the 2020 Updated European Consensus Guidelines.
Med. Sci. Monit. 2022, 28, e935632. [CrossRef]
Ranno, R.; Vestita, M.; Maggio, G.; Verrienti, P.; Melandri, D.; Orlandi, C.; Perniciaro, G.; De Angelis, A.; D’Alessio, R.; Mataro, I.;
et al. Italian recommendations on enzymatic debridement in burn surgery. Burns 2021, 47, 408–416. [CrossRef]
Serracanta, J.; Baena, J.; Martinez-Mendez, J.R.; Sanchez-Sanchez, M.; Lopez-Suso, E.; Galeiras, R.; Perez-De-Caz, M.D.; VivoBenlloch, C.; Monclus-Fuertes, E.; Casalduero-Viu, J.; et al. Bromelain-based enzymatic burn debridement: Spanish multidisciplinary consensus. Eur. J. Plast. Surg. 2023, 46, 271–279. [CrossRef] [PubMed]
Matsumura, H.; Ueda, T.; Ogawa, R.; Kaita, Y.; Sakurai, H.; Sasaki, J.; Soejima, K. Japanese Consensus Document on NexoBrid® , a
Burn Eschar Removal Agent. Jpn. J. Burn Inj. 2026, 52, 46–57. (In Japanese)
Dalkey, N.; Helmer, O. An experimental application of the Delphi method to the use of experts. Manag. Sci. 1963, 9, 458–467.
[CrossRef]
Schulz, A.; Shoham, Y.; Rosenberg, L.; Rothermund, I.; Perbix, W.; Fuchs, P.C.; Lipensky, A.; Schiefer, J.L. Enzymatic versus
traditional surgical debridement of severely burned hands: A comparison of selectivity, efficacy, healing time, and three-month
scar quality. J. Burn Care Res. 2017, 38, 745–755. [CrossRef] [PubMed]
Krieger, Y.; Rubin, G.; Schulz, A.; Rosenberg, N.; Levi, A.; Singer, A.J.; Rosenberg, L.; Shoham, Y. Bromelain-based enzymatic
debridement and minimal invasive modality (mim) care of deeply burned hands. Ann. Burns Fire Disasters 2017, 30, 198–204.
Schulz, A.; Fuchs, P.C.; Rothermundt, I.; Hoffmann, A.; Rosenberg, L.; Shoham, Y.; Oberländer, H.; Schiefer, J. Enzymatic
debridement of deeply burned faces: Healing and early scarring based on tissue preservation compared to traditional surgical
debridement. Burns 2017, 43, 1233–1243. [CrossRef] [PubMed]
Schulz, A.; Ribitsch, B.; Fuchs, P.C.; Lipensky, A.; Schiefer, J.L. Treatment of Genital Burn Injuries: Traditional Procedures and
New Techniques. Adv. Skin Wound Care 2018, 31, 314–321. [CrossRef]
Rosenberg, L.; Krieger, Y.; Bogdanov-Berezovski, A.; Silberstein, E.; Shoham, Y.; Singer, A.J. A novel rapid and selective enzymatic
debridement agent for burn wound management: A multi-center RCT. Burns 2014, 40, 466–474. [CrossRef]
Berner, J.E.; Keckes, D.; Pywell, M.; Dheansa, B. Limitations to the use of bromelain-based enzymatic debridement (NexoBrid® )
for treating diabetic foot burns: A case series of disappointing results. Scars Burn Heal. 2018, 4, 2059513118816534. [CrossRef]
Shoham, Y.; Rosenberg, L.; Narayan, R.P.; Staubach, R.; Bene, R.; Kakola, M.; Monstrey, S.J.; Wilson, Y.; Jha, M.; Lewis, G.M.; et al.
Open label randomized controlled trial of the efficacy and safety of NexoBrid compared to standard of care in children with
burns. Burns 2025, 51, 107417. [CrossRef]
Shoham, Y.; Krieger, Y.; Rubin, G.; Koenigs, I.; Hartmann, B.; Sander, F.; Schulz, A.; David, K.; Rosenberg, L.; Silberstein, E. Rapid
enzymatic burn debridement: A review of the paediatric clinical trial experience. Int. Wound J. 2020, 17, 1337–1345. [CrossRef]
Harats, M.; Haik, J.; Cleary, M.; Vashurin, I.; Aviv, U.; Kornhaber, R. A Retrospective Review of an Off-label Bromelain-based
Selective Enzymatic Debridement (Nexobrid® ) in the Treatment of Deep, Partial, and Full Thickness Burns and Hard to Heal
Wounds. Isr. Med. Assoc. J. 2020, 22, 83–88.
Schulz, A.; Fuchs, P.C.; Hans, N.; Opländer, C.; Valdez, L.B.; Schiefer, J.L. Inhibition of Bromelain Activity During Enzymatic
Debridement of Burn Wounds Pretreated with Frequently Used Products. J. Burn Care Res. 2018, 39, 413–422.
NexoBrid [Package Insert]; Kaken Pharmaceutical Co., Ltd.: Tokyo, Japan, 2024. (In Japanese)
NexoBrid [Early Post-Marketing Phase Vigilance Report]; Kaken Pharmaceutical Co., Ltd.: Tokyo, Japan, 2024. (In Japanese)
Nakazawa, H.; Ikeda, H.; Ichinohashi, K.; Ueda, T.; Ueda, T.; Osuka, A.; Kaita, Y.; Kimura, C.; Sakurai, H.; Shimada, K.; et al. The
Results of a Phase III Clinical Trial for a Novel Enzymatic Debridement Agent KMW-1 in Japanese Patient with Deep Dermal
Burn and Deep Burn. Jpn. J. Burn Inj. 2022, 48, 1–11. (In Japanese)
NexoBrid [Interview Form]; Kaken Pharmaceutical Co., Ltd.: Tokyo, Japan, 2024. (In Japanese)
Aoki, D.; Matsumura, H.; Tanaka, H.; Soejima, K.; Sasaki, J. [Next Generation of Burn Care: Burn Care in the New Era] Role of
Skin Banks for Burns. Prog. Med. 2023, 43, 677–682.
De Freitas, L.R.; Udoma-Udofa, O.C.; Reginato, P.H.; Costa Mitsui, H.; Provinciatto, H.; Torres, F.C. Bromelain-Based Enzymatic
Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis. J. Burn Care Res. 2025, 46,
123–131. [CrossRef] [PubMed]
Kaita, Y.; Nakajima, M.; Matsuda, T.; Yamaguchi, Y. Association of Combined Enzymatic and Surgical Debridement with Clinical
Outcomes in Extensive Burn Patients. J. Clin. Med. 2025, 14, 5233. [CrossRef]
Claes, K.E.Y.; De Decker, I.; Monstrey, S.; Shoham, Y.; Vyncke, T.; Depyperee, B.; De Wolf, E.; Decuypere, F.; Lannau, B.; Hoeksema,
H. Helpful hints in deciding what and when to operate after enzymatic debridement. Burns 2023, 49, 80–90. [CrossRef] [PubMed]
https://doi.org/10.3390/ebj7020029
Eur. Burn J. 2026, 7, 29
16 of 16
Morita, N.; Hamada, S.; Nakano, T. Changes in Burn Wound Surface and its Evaluation After Treatment with Nexobrid, a Necrotic
Tissue Removal Agent for Burn Wound. Jpn. J. Burn Inj. 2024, 50, 96–108. (In Japanese)
NexoBrid [Request for Proper Use]; Kaken Pharmaceutical Co., Ltd.: Tokyo, Japan, 2024. (In Japanese)
Wu, Z.Q.; Bulla, A.; Del Río, J.A.; Nicolls, D.A.; Sáez, J.A.; Domènech, J.S.; Barret, J.P. Enzymatic Debridement (Nexobrid) on
Burned Hands: Retrospective Review from a Burn Referral Center in Spain. Plast. Reconstr. Surg. Glob. Open 2024, 12, e5886.
Yoshida, D.; Tengan, S.; Ishii, M. Same-day Skin Grafting following Enzymatic Debridement using Nexobrid® : A Case Report.
Jpn. J. Burn Inj. 2024, 50, 123–126. (In Japanese)
Fischer, S.; Haug, V.; Diehm, Y.; Rhodius, P.; Cordts, T.; Schmidt, V.J.; Kotsougiani, D.; Horter, J.; Kneser, U.; Hirche, C. Feasibility
and safety of enzymatic debridement for the prevention of operative escharotomy in circumferential deep burns of the distal
upper extremity. Surgery 2019, 165, 1100–1105. [CrossRef]
Mataro, I.; Lanza, A.; Di Franco, S.; Di Franco, L.; Sangiuolo, M.; Notaro, M.; d’Alessio, R.; Villani, R. Releasing Burn-Induced
Compartment Syndrome by Enzymatic Escharotomy-Debridement: A Case Study. J. Burn Care Res. 2020, 41, 1097–1103. [CrossRef]
Tanaka, Y.; Kaita, Y.; Yoshikawa, K.; Yamaguchi, Y. A Case Report of Compartment Pressure Reduction Following Enzymatic
Debridement in Electrical Injury and Extensive Burns. Jpn. J. Burn Inj. 2025, 51, 112–116. (In Japanese)
NexoBrid [Package Insert]; Vericel Corporation: Durham, NC, USA, 2023.
Ikemoto, M.; Matsumura, Y.; Iwasawa, A.; Kimura, T. A study on the evaluation of safety of antiseptics using in vitro assay:
Evaluation method of cell viability using four cultured cell lines and seven kinds of antiseptics. J. Healthc. Assoc. Infect. 2022, 15,
5–15. (In Japanese)
Bozec, L.; Odlyha, M. Thermal denaturation studies of collagen by microthermal analysis and atomic force microscopy. Biophys. J.
2011, 101, 228–236. [CrossRef] [PubMed]
Kwa, K.A.A.; van Haasterecht, L.; Elgersma, A.; Breederveld, R.S.; Groot, M.L.; van Zuijlen, P.P.M.; Boekema, B.K.H.L. Effective
enzymatic debridement of burn wounds depends on the denaturation status of collagen. Wound Repair Regen. 2020, 28, 666–675.
[CrossRef]
Tapking, C.; Siegwar, L.C.; Jost, Y.; Hundeshagen, G.; Kotsougiani-Fischer, D.; Gazyakan, E.; Bliesener, B.; Kneser, U.; Fischer,
S. Enzymatic debridement in scalds is not as effective as in flame burns regarding additional eschar excision: A retrospective
matched-control study. Burns 2022, 48, 1149–1154. [CrossRef] [PubMed]
Aoki, K.; Komiya, T.; Yamashita, K.; Shimada, K.; Fujii, M.; Matsumura, H. A Pilot Study to Evaluate the Minimally Invasive Burn
Care for Small, Deep Partial-Thickness Burns of the Hands and Feet Using Enzyme Debridement and Autologous Skin Cell Spray.
J. Clin. Med. 2024, 13, 7721. [CrossRef]
Shoham, Y.; Gasteratos, K.; Singer, A.J.; Krieger, Y.; Silberstein, E.; Goverman, J. Bromelain-based enzymatic burn debridement:
A systematic review of clinical studies on patient safety, efficacy and long-term outcomes. Int. Wound J. 2023, 20, 4364–4383.
[CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
https://doi.org/10.3390/ebj7020029